Leto G, Tumminello F M, Pizzolanti G, Montalto G, Soresi M, Carroccio A, Ippolito S, Gebbia N
Section of Chemotherapy, Faculty of Medicine, University of Palermo, Italy.
Pancreas. 1997 Jan;14(1):22-7. doi: 10.1097/00006676-199701000-00004.
Lysosomal cathepsins D (CD), B (CB), and L (CL) serum levels were determined by immunoassays in patients with chronic (CHP) or acute (AP) pancreatitis and in patients with ductal pancreatic carcinoma (DPC) and correlated with some biological and clinical parameters of this tumor. CB serum concentrations significantly higher than those measured in healthy subjects (NS) were observed in CHP, AP, and DPC patients (p < 0.01). However, no significant difference was noted among these groups. Increased CL serum levels were evident only in cancer patients compared to NS, AP, or CHP groups (p < 0.05), while no difference was observed among these groups. Elevated CD serum values were observed in CHP and AP patients compared to healthy subjects or cancer patients (p < 0.01). In cancer patients no correlation between CD, CB, and CL and clinical stage or tumor size was found. However, significant correlations were observed only between serum CD and CA50 (p < 0.02) and between CD and CL (p < 0.05). No further relationship among the biochemical parameters examined was observed. The present data suggest that the different serum patterns of CD, CB, and CL in patients with pancreatitis and pancreatic cancer may be of clinical interest as additional biochemical parameters for the differential diagnosis of these diseases. However, further prospective clinical studies are needed to assess better their potential value as prognostic parameters to identify patients with pancreatitis at increased risk to develop pancreatic cancer.
通过免疫测定法测定了慢性胰腺炎（CHP）或急性胰腺炎（AP）患者以及胰腺导管癌（DPC）患者的溶酶体组织蛋白酶D（CD）、组织蛋白酶B（CB）和组织蛋白酶L（CL）的血清水平，并将其与该肿瘤的一些生物学和临床参数相关联。在CHP、AP和DPC患者中观察到CB血清浓度显著高于健康受试者（NS）中的测量值（p < 0.01）。然而，这些组之间未观察到显著差异。与NS、AP或CHP组相比，仅在癌症患者中CL血清水平明显升高（p < 0.05），而这些组之间未观察到差异。与健康受试者或癌症患者相比，CHP和AP患者的CD血清值升高（p < 0.01）。在癌症患者中，未发现CD、CB和CL与临床分期或肿瘤大小之间存在相关性。然而，仅在血清CD与CA50之间（p < 0.02）以及CD与CL之间（p < 0.05）观察到显著相关性。在所检测的生化参数之间未观察到进一步的关系。目前的数据表明，胰腺炎和胰腺癌患者中CD、CB和CL的不同血清模式作为这些疾病鉴别诊断的额外生化参数可能具有临床意义。然而，需要进一步的前瞻性临床研究来更好地评估它们作为预后参数的潜在价值，以识别患胰腺癌风险增加的胰腺炎患者。
